Home Featured Page 177

Featured

Latest

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its...

Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for...

Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC;...

Horizons: Grounds for Collective Effervescence

Numinus Wellness Inc. Reports Q1 2022 Results

PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor...

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive...

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase...

PT286 – Joe Tafur, MD – Vital Psychedelic Conversations

Psychedelic Company Highlights in 2021

1...176177178...291 Page 177 of 291

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its...

Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for...

Psychedelic Bulletin: DEA Moves to Schedule 5 Tryptamines; Eleusis Unveils SPAC;...

Horizons: Grounds for Collective Effervescence

Numinus Wellness Inc. Reports Q1 2022 Results

PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor...

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive...

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase...

PT286 – Joe Tafur, MD – Vital Psychedelic Conversations

Psychedelic Company Highlights in 2021

EDITOR PICKS

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY